Hereditary Angioedema
📧 Sign up to get email alerts when something new happens for Hereditary Angioedema.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-06-29Clinical Trial Update: CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks [Phase 3]
Phase 3 trial update for garadacimab (CSL312) in preventing hereditary angioedema attacks has completed with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-06-26Clinical Trial Update: Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema [Phase 3]
Expanded access program update for lanadelumab in Japanese patients with hereditary angioedema; Phase 3 study completed and results posted.
-
CLINICAL_TRIALS trial_result · 2023-06-18Clinical Trial Update: A Long Term Safety Study of BCX7353 in Hereditary Angioedema [Phase 2, Phase 3]
Long-term safety study of BCX7353 in hereditary angioedema has completed phases 2 and 3 with results posted.
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II [Phase 2]
A Phase II cross-over study evaluating the efficacy and safety of KVD900 (Sebetralstat) for on-demand treatment of hereditary angioedema att…
-
CLINICAL_TRIALS trial_result · 2022-11-08Clinical Trial Update: A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) [Phase 2]
Phase 2 trial of CSL312 in hereditary angioedema completed; results posted in 2022.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-09-28Clinical Trial Update: A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema [Phase 2]
Phase 2 clinical trial evaluating the efficacy of donidalorsen (IONIS-PKK-LRx/ISIS 721744) in hereditary angioedema has completed with poste…
-
CLINICAL_TRIALS trial_result · 2022-09-19Clinical Trial Update: Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE) [Phase 3]
Phase 3 study evaluating efficacy and safety of lanadelumab (SHP643) in Japanese participants with hereditary angioedema has completed with …
-
CLINICAL_TRIALS trial_result · 2022-05-26Clinical Trial Update: A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children [Phase 3]
Phase 3 clinical trial evaluating lanadelumab for preventing hereditary angioedema attacks in children has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-03-29Clinical Trial Update: A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema [Phase 3]
Phase 3 trial of icatibant (TAK-667) in Japanese children and adolescents with acute attacks of hereditary angioedema has completed with res…
-
CLINICAL_TRIALS trial_result · 2021-05-18Clinical Trial Update: EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema [Phase 2]
Phase 2 clinical trial assessing DX-88 (conestat alfa) for reducing angioedema episodes in hereditary angioedema; study completed.
-
CLINICAL_TRIALS trial_result · 2021-04-01Clinical Trial Update: Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema [Phase 2]
Phase 2 trial update for BCX7353 in hereditary angioedema completed with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-03-04Clinical Trial Update: Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan [Phase 3]
This clinical trial update reports the completion of a Phase 3 study evaluating BCX7353, an oral therapy, for preventing hereditary angioede…
-
CLINICAL_TRIALS trial_result · 2021-03-04Clinical Trial Update: Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema [Phase 2]
Phase 2 trial updating efficacy and safety of BCX7353 to prevent angioedema attacks in hereditary angioedema (HAE).
-
CLINICAL_TRIALS trial_result · 2021-03-02Clinical Trial Update: Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE [Phase 3]
Phase 3 trial update for BCX7353 as an oral preventive treatment for hereditary angioedema (HAE) completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-02-01Clinical Trial Update: A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route [Phase 1, Phase 2]
A clinical trial evaluating the pharmacology and safety of subcutaneously administered C1-esterase inhibitor in hereditary angioedema types …
-
CLINICAL_TRIALS trial_result · 2021-01-29Clinical Trial Update: A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema [Phase 3]
Phase 3 trial evaluating subcutaneous C1-esterase inhibitor for prevention of hereditary angioedema completed.
-
CLINICAL_TRIALS trial_result · 2020-05-11Clinical Trial Update: Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE [Phase 3]
Phase 3 long-term safety and efficacy study of DX-2930 (SHP643) for preventing acute angioedema attacks in patients with Hereditary Angioede…
-
CLINICAL_TRIALS trial_result · 2019-08-08Clinical Trial Update: A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants [Phase 3]
Phase 3 trial of icatibant for acute attacks of hereditary angioedema in Japanese participants completed; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-03-25Clinical Trial Update: A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema [Phase 3]
Phase 3 pharmacokinetic, tolerability, and safety study of icatibant in children and adolescents with hereditary angioedema has completed wi…
-
CLINICAL_TRIALS trial_result · 2018-12-31Clinical Trial Update: Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE) [Phase 3]
Phase 3 trial of C1 inhibitor (human) for prevention and treatment of breakthrough attacks in Japanese subjects with hereditary angioedema h…
-
CLINICAL_TRIALS trial_result · 2018-11-28Clinical Trial Update: Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema [Phase 3]
A Phase 3 study evaluated subcutaneously administered C1 esterase inhibitor for prevention of angioedema attacks in adolescents and adults w…
-
CLINICAL_TRIALS trial_result · 2018-11-14Clinical Trial Update: A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema [Phase 3]
Phase 3 trial evaluating long-term safety and efficacy of subcutaneously administered C1-esterase inhibitor for prevention of hereditary ang…
-
CLINICAL_TRIALS trial_result · 2018-09-06Clinical Trial Update: Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects [Phase 1]
Phase 1 study evaluating safety, tolerability, and pharmacokinetics of recombinant human C1 esterase inhibitor in healthy adults completed; …
-
CLINICAL_TRIALS trial_result · 2018-08-28Clinical Trial Update: Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema [Phase 3]
Phase 3 trial assessing safety and efficacy of CINRYZE for prevention of angioedema attacks in children 6-11 with hereditary angioedema; stu…
-
CLINICAL_TRIALS trial_result · 2018-04-24Clinical Trial Update: Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE [Phase 3]
Phase 3 trial evaluating DX-2930 for preventing acute angioedema attacks in patients with hereditary angioedema (HAE).